EXECUTIVE FORUM ON DIGITAL PATHOLOGY MANAGEMENT 2

Why It Matters

Accelerating digital pathology adoption boosts diagnostic speed and accuracy, reshaping clinical labs and creating new biotech partnership opportunities.

Key Takeaways

• Mayo Clinic leads digital innovation in pathology labs
• Gestalt Diagnostics outlines market growth and AI opportunities
• LigoLab emphasizes seamless IMS‑LIS integration for efficiency
• Advances promise faster diagnoses and reduced operational costs

Pulse Analysis

Digital pathology is moving from niche research tools to core components of modern clinical laboratories. According to recent market analyses, the global digital pathology market is projected to exceed $2 billion by 2028, driven by AI‑powered image analysis, cloud‑based data storage, and the need for remote diagnostics accelerated by the pandemic. Leaders such as Mayo Clinic are investing heavily in end‑to‑end digital workflows, which not only improve turnaround times but also generate large, structured datasets that fuel machine‑learning models for disease detection.

A critical bottleneck in realizing these benefits is the integration of laboratory information systems (LIS) with image management solutions (IMS). Vendors like LigoLab and PathPresenter are championing seamless IMS‑LIS connectivity, allowing pathologists to access high‑resolution slides directly within existing electronic health‑record environments. This reduces manual data entry, minimizes errors, and supports real‑time collaboration across institutions. The forum highlighted that standardized APIs and interoperable data standards are becoming essential for scaling digital pathology across multi‑site health networks.

Looking ahead, the convergence of AI, high‑throughput imaging, and robust data integration promises to transform pathology from a largely manual specialty into a data‑driven discipline. Faster, more accurate diagnoses will enable personalized treatment plans, while the generated analytics open new revenue streams for hospitals through licensing of de‑identified datasets. Investors are taking note, with venture capital flowing into startups that combine AI algorithms with seamless lab integration, signaling a sustained growth trajectory for the digital pathology ecosystem.